Prudential PLC Sells 9,191 Shares of IQVIA Holdings Inc. $IQV

Prudential PLC lessened its holdings in IQVIA Holdings Inc. (NYSE:IQV) by 17.7% during the fourth quarter, HoldingsChannel.com reports. The firm owned 42,690 shares of the medical research company’s stock after selling 9,191 shares during the period. Prudential PLC’s holdings in IQVIA were worth $9,623,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in the business. Brighton Jones LLC increased its holdings in IQVIA by 244.4% during the fourth quarter. Brighton Jones LLC now owns 3,575 shares of the medical research company’s stock worth $703,000 after buying an additional 2,537 shares during the last quarter. Empowered Funds LLC increased its holdings in IQVIA by 102.1% during the first quarter. Empowered Funds LLC now owns 9,728 shares of the medical research company’s stock worth $1,715,000 after buying an additional 4,915 shares during the last quarter. Sivia Capital Partners LLC acquired a new position in IQVIA during the second quarter worth $514,000. First Trust Advisors LP increased its holdings in IQVIA by 14.8% during the second quarter. First Trust Advisors LP now owns 92,015 shares of the medical research company’s stock worth $14,501,000 after buying an additional 11,845 shares during the last quarter. Finally, NewEdge Advisors LLC increased its holdings in IQVIA by 5.4% during the second quarter. NewEdge Advisors LLC now owns 22,731 shares of the medical research company’s stock worth $3,582,000 after buying an additional 1,155 shares during the last quarter. Institutional investors own 89.62% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts recently weighed in on IQV shares. Truist Financial lowered their target price on shares of IQVIA from $290.00 to $245.00 and set a “buy” rating on the stock in a report on Thursday, February 19th. Evercore restated an “outperform” rating and set a $185.00 target price on shares of IQVIA in a report on Wednesday, April 8th. Jefferies Financial Group lowered their target price on shares of IQVIA from $270.00 to $255.00 and set a “buy” rating on the stock in a report on Friday, February 6th. UBS Group lowered their target price on shares of IQVIA from $280.00 to $240.00 and set a “buy” rating on the stock in a report on Friday, February 6th. Finally, Citigroup lowered their target price on shares of IQVIA from $230.00 to $200.00 and set a “neutral” rating on the stock in a report on Friday, February 6th. Two research analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and two have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Buy” and an average price target of $224.13.

IQVIA Price Performance

NYSE:IQV opened at $183.56 on Friday. IQVIA Holdings Inc. has a one year low of $147.62 and a one year high of $247.04. The company has a market cap of $30.64 billion, a P/E ratio of 22.75, a P/E/G ratio of 1.60 and a beta of 1.21. The firm’s fifty day moving average price is $172.12 and its two-hundred day moving average price is $194.94. The company has a debt-to-equity ratio of 2.20, a current ratio of 0.75 and a quick ratio of 0.75.

IQVIA (NYSE:IQV) last released its quarterly earnings data on Tuesday, May 5th. The medical research company reported $2.90 EPS for the quarter, beating the consensus estimate of $2.83 by $0.07. IQVIA had a net margin of 8.33% and a return on equity of 30.50%. The firm had revenue of $4.15 billion for the quarter, compared to the consensus estimate of $4.10 billion. During the same period in the previous year, the company earned $2.70 earnings per share. The company’s quarterly revenue was up 8.4% on a year-over-year basis. IQVIA has set its FY 2026 guidance at 12.650-12.950 EPS. Equities analysts expect that IQVIA Holdings Inc. will post 11.6 earnings per share for the current year.

IQVIA announced that its Board of Directors has initiated a share buyback plan on Thursday, May 7th that allows the company to repurchase $2.00 billion in shares. This repurchase authorization allows the medical research company to reacquire up to 6.8% of its shares through open market purchases. Shares repurchase plans are usually an indication that the company’s board believes its stock is undervalued.

IQVIA Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.